New horizons in tumor microenvironment biology: challenges and opportunities
By Fei Chen, Xueqian Zhuang, Liangyu Lin, P. Yu, Ying Wang, Yufang Shi, G. Hu, Yu Sun. BMC Medicine, 2015
681 citations recorded by the source corpus.
The tumor microenvironment (TME) is being increasingly recognized as a key factor in multiple stages of disease progression, particularly local resistance, immune-escaping, and distant metastasis, thereby substantially impacting the future development of frontline interventions in clinical oncology. An appropriate understanding of the TME promotes evaluation and selection of candidate agents to control malignancies at both the primary sites as well as the metastatic settings. This review presents a timely outline of research advances in TME biology and highlights the prospect of targeting the TME as a critical strategy to overcome acquired resistance, prevent metastasis, and improve therapeutic efficacy. As benign cells in TME niches actively modulate response of cancer cells to a broad range of standard chemotherapies and targeted agents, cancer-oriented therapeutics should be combined with TME-targeting treatments to achieve optimal clinical outcomes. Overall, a body of updated information is delivered to summarize recently emerging and rapidly progressing aspects of TME studies, and to provide a significant guideline for prospective development of personalized medicine, with the long term aim of providing a cure for cancer patients.
Subfields: Biotechnology, Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/b55be59deaf313855dba891ef8ed0f4aadc7f777
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
- G. Brooks
- C. Roma-Rodrigues
- Alexandra R. Fernandes
- R. Mendes
- Thea D. Tlsty
- Pedro Viana Baptista
- Philippe Gascard
Citations in the corpus
- Role of hypoxia in cancer therapy by regulating the tumor microenvironment (2019, background): “The TME decreases drug penetration and confers the advantage of proliferation and antiapoptosis to surviving cells, facilitating resistance and common modifications in disease morphology [4, 5].”
- The Science and Translation of Lactate Shuttle Theory. (2018, background): “Lactate Influences Acidity of the Tumor Microenvironment (TME) The TME is an active niche that shapes tumor pathogenesis and evolution (Chen et al., 2015).”
- Role of interleukin-6 in cancer progression and therapeutic resistance (2016, neutral): “therapeutic gain and tumour-free survival [163].”
- Targeting Tumor Microenvironment for Cancer Therapy (2019, background): “The TME consists of extracellular matrix (ECM), stromal cells (such as fibroblasts, mesenchymal stromal cells, pericytes, occasionally adipocytes, blood and lymphatic vascular networks) and immune cells (including T and B lymphocytes, natural killer cells and Tumor-associated macrophages) [6].”
- Carcinoma-associated fibroblasts: orchestrating the composition of malignancy (2016, background): “…2011; Lecomte et al. 2012; McDonald et al. 2015), adipocytes (Bochet et al. 2013), endothelial cells (Zeisberg et al. 2007), or even, perhaps, epithelial cells (Radisky et al. 2007) that undergo mesenchymal transition when instructed by systemic factors secreted by the tumor (Chen et al. 2015a).”